Volume : 13, Issue : 07, July – 2026
Title:
FORMULATION AND EVALUATION OF BUPRENORPHINE TRANSDERMAL PATCHES BY USING NATURAL POLYMER
Authors :
Kundavarapu Narendra, A. Gopireddy*, Indira Revathi, Annapureddi
Abstract :
The objective of present study was to develop matrix type transdermal therapeutic systems of Buprenorphine using various such as chitosan and tragacanth gum polymers as matrix formers. Results revealed that prepared patches showed good physical characteristics, no drug-polymer interaction. The in vitro release study revealed that F4 formulation showed maximum release in 8 hrs. Formulation F4 was subjected for accelerated stability studies. The F4 formulation was found to be stable as there was no drastic change in the Physico-chemical properties of the patches, which was also confirmed by FTIR. Thus conclusion can be made that stable transdermal patches of has been developed. F4 formulation showed highest cumulative percentage drug release of 95.90% were obtained during in vitro drug release studies after 8 hrs. The release of Buprenorphine appears to be dependent on lipophilicity of the matrix. Moderately lipophillic matrices showed best release. The predominant release mechanism of drug through the fabricated matrices was believed to be by diffusion mechanism. Based upon the in vitro dissolution data the F4 formulation was concluded as optimized formulation.
Key words: Buprenorphine, Chitosan, tragacanth gum solvent casting technique, in vitro drug release studies.
Cite This Article:
Please cite this article in press Sayed Shaffath Ali et al Formulation And Evaluation Of Buprenorphine Transdermal Patches By Using Natural Polymer, Indo Am. J. P. Sci, 2026; 13(07).
REFERENCES:
1. Vyas S.P and Khar R.K. Targetted and controlled Drug Delivery Novel carrier system1st ed. CBS Publishers and distributors, New Delhi, 2002; 411- 447.
2. Chein Y.W. Transdermal drug delivery and delivery system. In, Novel drug delivery system, Vol. 50, Marcel Dekker, Inc., New york, 1992 pp.301-381.
3. Martin A, Swabrik J, Cammarara A. Physical pharmacy. 4th ed. New delhi: B.I Vaverly Pvt Ltd; 1996: 264-8.
4. R.L Cleek, A.L Bunge, “A new method for estimating dermal absorption from chemical exposure.General approach”, Pharm Res, Vol.10, 497–506, 1993.
5. Hadgraft, J., Guy, R., In; Transdermal Drug Delivery, Marcel Dekker, Inc., New York and Basel, Vol. 35, 296.
6. Misra, A.N., In; Jain, N.K., Eds., Controlled and Novel Drug Delivery, 1st ed. CBS Publishers and Distributors, New Delhi, 2002, 101-107.
7. Loyd v. allen, Jr. Nicholas G. popovich, howard C. Ansel. Pharmaceutical dosage form and drug delivery systems. 8th ed. Wolters kluwer publishers, New delhi, 2009; 298-315.
8. Ghosh, T.K., Pfister, W.R., Transdermal and Topical Drug Delivery Systems, Int. Pharm., Press, 39.
9. Berner B, John VA (February 1994). “Pharmacokinetic characterization of transdermal delivery systems”. Clinical pharmacokinetics 26 (2): 121–34. PMID 8162656.
10. Shreeraj183: Transdermal drug delivery technology revisited: recent advances.
11. Breathnach AS. An Atlas of the Ultrastructure of Human Skin. London: Churchill, 1971.
12. Hashimoto K, Gross BG, Lever WF. The ultrastructure of the skin of human embryos. II. The formation of intradermal portion of the eccrine sweat duct and of the secretory segment during the first half of embryonic life. J Invest Dermatol 1966; 46: 513–29.
13. Roberts MS, Targeted drug delivery to the skin and deeper tissues: role of physiology, solute structure and disease.Clin Exp Pharmacol Physiol 1997 Nov; 24(11):874-9.